Poster presented at ACR 2013 reveals results on the use of biologic monotherapy in RA
We were delighted to present the poster, ‘The evolving use of biologic monotherapy in RA and its impact on patient outcomes’ at the ACR Annual Meeting’13 in San Diego. The poster references data from our syndicated study Therapy Watch RA amongst rheumatologists in Europe.
China's Chronic Disease Challenge
260 million people from mainland China now suffer from a chronic disease condition such as diabetes because of lifestyle factors including smoking, lack of exercise and a high-fat diet. Apart from the particularly high smoking rate, most other developed nations have similar risk profiles. Yet the World Health Organisation (W.H.O) reports that 85% of deaths each year in China are from chronic illness, significantly more than anywhere else in the developed world.
Poster on the use of biologic monotherapy in Rheumatoid Arthritis accepted at ACR 2013
Research Partnership has been asked to present a poster at the forthcoming ACR Conference in San Diego this year. Entitled “The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes”, the poster is authored by Associate Director Laurent Chanroux and references data from our syndicated study amongst physicians in Europe.
Barriers to Biologic Treatment - Is Injecting Such a Pain?
Published in Eye for Pharma 10 October 2013 By Mary Assimakopoulos
Mary Assimakopoulos examines a common yet often unaddressed patient concern – the very human fear of needles!Insights from our market research into autoimmune diseases clearly demonstrate that patients who are treated with a biologic are more satisfied with their treatment, report significant improvements in their symptoms, are more likely to be able to live a “normal” life and have more positive feelings about coping with their disease. Biologic treatments halt the progression of the illness, rather than just deal with the symptoms.